Presentations & Publications
Preclinical Immunogenicity and Efficacy of VRON-0200: A Novel Therapeutic Vaccine for Potential Functional Cure Therapies in Patients with Chronic HBV
Hasanpourghadi M, et al.
APASL, Abstract #OP-0685
Dr. Hildegund Ertl, Professor in the Vaccine & Immunotherapy Center at The Wistar Institute and the Scientific Founder of Virion Therapeutics, LLC, presented data on VRON-0200 chronic hepatitis B virus (HBV) program at Asian Pacific Association for the Study of the Liver (APASL) Seoul 2022. [7:30 mins].